ClinicalTrials.gg
CompletedNCT06222294Updated Jan 9, 2026

A Study of Remimazolam Tosilate for Sedation in the ICU

A Phase 3 interventional study of Remimazolam Tosilate and Propofol Medium and Long Chain Fat Emulsion Injection in Sedation in the ICU, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in the ICU.

02

Conditions studied

  • Sedation in the ICU
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients and/or their guardians are able to provide a written , understand and agree to comply with the study requirements and protocol.
  2. Subjects have been treated with endotracheal intubation and mechanical ventilation, and are expected to receive sedation after randomization at least 6 hours. The target sedation level during the period is -2 ≤ RASS ≤ +1.
  3. 18 years to 80 years old, male or female.
  4. 18 kg/m2 ≤ ≤ 30 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Deep sedation is required, or continuous sedation is not needed during the study process.
  2. Participants (other than in endotracheal intubation) who are expected to require neuro-muscle blockers during sedation.
  3. History of epilepsy or status epilepticus.
  4. Myasthenia gravis or a history of myasthenia gravis.
  5. Severe arrhythmias or heart disease; the circulatory system is unstable.
  6. Subjects with a history of severe cardiovascular disease, or cerebrovascular disease, or neurological disease, or mental illness.
  7. Subjects with a history of drug abuse.
  8. Organ failure before randomization.
  9. Abnormal values of the laboratory examination.
  10. Allergic to relevant drugs ingredient or component.
  11. Pregnant or nursing women.
  12. Subjects who has participated in clinical trials of other interventions recently.
  13. Other conditions deemed unsuitable to be included.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    Remimazolam Tosilate for Injection

    Drug: Remimazolam Tosilate

  • Active comparator
    Propofol Medium and Long Chain Fat Emulsion Injection

    Drug: Propofol Medium and Long Chain Fat Emulsion Injection

Interventions

  • Loading dose: 0.08mg/kg Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h

  • DrugPropofol Medium and Long Chain Fat Emulsion Injection

    Loading dose: 0.3-0.5mg/kg Maintenance dose: IV Propofol Medium and Long Chain Fat Emulsion Injection, dose range 0.3-4.0mg/kg/h, increment or decrement of 0.3-0.6mg/kg/h

06

What researchers measure

Primary outcomes

  1. Rate of sedation success, sedation success is defined as the percentage of time maintaining target sedation in the entire drug administering time ≥ 70% without rescue sedation.

    Time frame: within 24 hours after administration of research drug

Secondary outcomes

  1. Percentage of time maintaining target sedation in the entire drug administering time.

    Time frame: within 24 hours after administration of research drug

  2. Percentage of subjects receiving rescue sedation

    Time frame: within 24 hours after administration of research drug

  3. The number of additional doses of the research drug

    Time frame: within 24 hours after administration of research drug]

  4. The total dosage of Fentanyl

    Time frame: within 24 hours after administration of research drug

  5. Wake-up time.

    Time frame: within 6 hours after stopping the research drug

  6. Stopping the research drug to extubation time.

    Time frame: within 6 hours after stopping the research drug

  7. Nursing scale score

    Time frame: follow-up period (approx. 5-10 minutes)

07

Study locations

1 site
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
08

References and documents

Publications

  • Guan X, Liu N, Lin F, Yu J, Yang M, Zhou Q, Chen K, Yu X, Huang X, Zhu J, Lyu J, Gui C, Hu Z, Zheng S, He B, Wang M, Yu Z, Ma X, Lv A, Zhang J, Xu J, Ye J, Gong J, Tian X, Zhou J, Zhou F, Yu L, He W, Li X, Yin T, Zhao H, Ding Y, Chen M. Efficacy and Safety of Remimazolam Tosylate versus Propofol for Sedation of Postoperative Mechanically Ventilated Patients in Intensive Care Units: A Multicenter, Randomized, Single-blind, Noninferiority, Phase 3 Trial. Anesthesiology. 2026 Jul 1;145(1):72-83. doi: 10.1097/ALN.0000000000006047. Epub 2026 Mar 19. PubMed 41855428 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Aug 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2023
First posted
Jan 24, 2024
StartActual
Mar 12, 2024
Primary completionActual
Aug 13, 2024
CompletionActual
Sep 24, 2024
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06222294
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
Mar 12, 2024
Primary completion
Aug 13, 2024
Completion
Sep 24, 2024
Last update
Jan 9, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion